Lineage Therapeutics launches generic epinephrine auto-injector in US markets
Lineage Therapeutics Inc. has launched generic epinephrine injection, a USP auto-injector, for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis, in US market. The injection is the authorized generic of Adrenaclick by Amedra Pharmaceuticals LLC.
The product is available as a two-pack carton in both 0.15 mg and 0.30 mg strengths.
Anaphylaxis is a potentially life-threatening allergic reaction that is rapid in onset and may cause severe swelling, breathing problems, loss of blood pressure, and death. Allergic reactions can be caused by stinging and biting insects (bugs), allergy injections, food, medicines, exercise, or unknown causes. Symptoms may include closing of the breathing airways, wheezing, sneezing, hoarseness, hives, itching, swelling, skin redness, fast heartbeat, weak pulse, feeling very anxious, confusion, and stomach pain. Epinephrine is the medicine of choice for someone experiencing an anaphylactic reaction. Prompt recognition of the signs and symptoms of anaphylaxis is crucial.
Lineage's epinephrine auto-injector is the only generically priced epinephrine auto-injector currently available. This authorized generic epinephrine injection, USP auto-injector, is being reintroduced to the market as it was previously marketed under prior ownership.
According to Dr F Estelle R Simons, professor, Department of Pediatrics & Child Health at the University of Manitoba, "There is a long-standing need for an inexpensive epinephrine auto-injector."
Epinephrine auto-injectors, 0.15 mg and 0.30 mg, had US sales of approximately $758 million for the 12 months ending April 30, 2013, according to IMS Health.